Altem Technologies has partnered with Cellink to accelerate lifescience research with 3D bioprinting in the Indian market. With this partnership, Altem intends to establish a strong presence of bioprinting in the field of medical research and lifescience applications, the companies said in a joint statement.
It also said that the partnership with Altem enables Cellink to expand its footprint in the Indian market, providing bioprinting knowhow to researchers to conduct in-vitro studies and reduce the product development time of drugs and medicines.
Commenting on the partnership with Cellink, Sharath Chandra, co-founding Director, Altem Technologies, said, “India has much potential in drug and medicine development and requires more specialised technologies to deliver the future services in lifescience and healthcare. Through this partnership, we invest in making strategic efforts in identifying and nurturing the 3D-bioprinting development opportunities for India. The outcome of this partnership will be to engage and respond to future trends of medicine and healthcare with bio-convergence solutions.”
Altem’s team of specialists with high expertise in lifescience is now working with some of the top research institutes and hospitals in India to bring revolutionary products to healthcare, notified the statement.
Cecilia Edebo, CEO, Cellink Bioprinting, said, “The convergence of robotics-AI-genomics-bioprinting can contribute to improved quality and future of healthcare. Given the larger addressable population and growing demands for precision medicine, there is a pressing need for addressing the healthcare requirements on priority, and it calls for accelerated research on the future of healthcare. Our partnership with Altem will contribute in the direction of developing the technology of tomorrow for creating a better quality of life.”